Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CagriSema for weight loss in adults with overweight or obesity
NL-OMON59892Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CagriSema, cagrilintide and semaglutide in obesity and Overweight (4 arms), sponsored by Novo Nordisk. Primary endpoints: Relative change in body weight and Achievement of at least 5% weight reduction. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON59892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59892.